Navigation Links
HS-7 Document Regarding Research @ M. D. Anderson Orlando
Date:9/3/2009

GREENVILLE, S.C., Sept. 3 /PRNewswire/ -- HS Pharmaceuticals, LLC and its business partner 7 Oaks Pharmaceutical Corporation have engaged in a collaborative research agreement with M. D. Anderson Cancer Center Orlando to study the effects of its proprietary and patented research compound, HS-7, as an effective treatment for pancreatic cancer. The first preclinical study has shown encouraging results and additional studies are now underway.

The research was conducted by Dr. Cheryl Baker, Director and Assistant Professor, Cancer Research Institute of M. D. Anderson Cancer Center Orlando. In a double-blinded study, HS-7 was injected into nude mouse models impregnated with human pancreatic cancer tissue. Reported results indicate that HS-7 demonstrated promising anti-cancer activity. Dr. Baker will continue with the next phase of preclinical studies and M. D. Anderson Cancer Center Orlando will work with HS Pharmaceuticals, LLC and 7 Oaks Pharmaceutical Corporation to progress the HS-7 compound into Phase 1 clinical trials for pancreatic cancer.

The companies have also contracted with Dr. Thomas Wagner (Director, Oncology Research Institute, Greeneville Hospital System) and Dr. Gunter Schwamberger (Professor, University of Salzburg, Austria) to research additional oncology applications for HS-7. Dr. Wagner and Dr. Schwamberger are now conducting animal studies on the compound's effect in melanoma, lymphoma, leukemia, and sarcoma models.


'/>"/>
SOURCE HS Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. University of Redlands Student Cody Unser Documentary Run to Start Today in L.A.
2. Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use
3. Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
4. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
5. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
6. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
7. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
8. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
9. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
10. MannKind Addresses Pfizers Announcement Regarding Exubera
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a family ... and Raleigh regions, is organizing an extended charity drive to benefit the family ... abnormality. , After struggling since birth with several health challenges, T.J. was later ...
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
Breaking Medicine News(10 mins):